Biotech Research News: H.C. Wainwright & Co. Initiates
Coverage of GenSpera (OTCQB:GNSZ) with a Buy Rating
New York, NY - December 17, 2014 (Investorideas.com Biotech
Newswire) Market Exclusive announces that H.C. Wainwright & Co has
initiated coverage with a Buy rating of GenSpera, Inc. (OTCQB:GNSZ) and a 12-month target price of $2.
According
to the H.C Wainwrights & Co. report, "if successful, Genspera's
platform could help provide a novel way to deliver drugs with higher efficiency
to specific hard-to-treat cancers, such as HCC and GBM."
GenSpera, Inc., headquartered in San
Antonio, Texas, is a biotechnology company specializing in the development of
targeted prodrug agents for the treatment of various solid cancers.
About Market Exclusive
Market Exclusive is a financial portal
geared to engaging discussion on current financial topics. Market Exclusive is
not an investment advisor.
The owner of this announcement warrants
that: (i) the releases contained herein are protected by copyright and other
applicable laws; and (ii) they are solely responsible for the content, accuracy
and originality of the information contained therein.
SOURCE: Market Exclusive
Read this release
in full at: http://www.investorideas.com/CO/GNSZ/news/2014/12171.asp
About GenSpera
GenSpera's
technology platform combines a powerful, plant-derived cytotoxin (thapsigargin)
with a prodrug delivery system that provides for the targeted release of drug
candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin
results in cell death irrespective of the rate of cell division, which may
provide an effective approach to kill both fast- and slow-growing cancers.
GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA,
which is found at high levels in the vasculature of liver and glioblastoma
cancers and in the vasculature of almost all other solid tumors. Mipsagargin is
expected to have potential efficacy in a wide variety of tumor types.
The
US Food and Drug Administration (FDA) granted Orphan Drug designation in 2013
for the evaluation of mipsagargin in patients with hepatocellular carcinoma.
Mipsagargin Phase II clinical trials are underway in both hepatocellular
carcinoma (liver cancer) and glioblastoma patients (brain cancer).
For
more information, please visit the company's website: www.genspera.com or follow us on
Twitter @GenSperaNews.
Disclaimer/ Disclosure: Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: Genspera (GNSZ) has engaged Investor Ideas for PR and news
publication effective June 18, 2014 (compensation of five thousand per month
and average of eleven thousand five hundred 144 shares per month)
BC Residents and Investor Disclaimer:
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
Become an
Investorideas.com Member and access our 14 online stock directories 24/7 –biotech,
mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/
Any redistribution or
publishing of information from our newsletter alerts and e-mails without the
written consent of Investorideas.com is strictly forbidden
Offloading of positions by speculators amid subdued demand in the
ReplyDeletespot market mainly influenced chana prices at futures trade. epicresearch.co